Teewinot Life Sciences Corporation: At the Vanguard of Biopharmaceutical Cannabinoid Therapeutics

• Global medicinal cannabinoid market to exceed $55 billion by 2025
• Teewinot has created patent protected methods to produce exact cannabinoid molecules called CANNSYNTHESIS®
• Efficient cost-effective methods reduce production time and increase purity

There is indisputable scientific evidence of the curative effects of cannabinoids, and specialty biopharmaceutical companies are positioning to capitalize on the explosive growth expected in the cannabinoid-derived pharmaceutical market. In a report that may be substantially underestimated, the global medical cannabinoid market is expected to exceed $55 billion by 2025 (http://ibn.fm/stG53). However, the discovery of the human endocannabinoid system dramatically changed both the understanding and the vast potential of cannabinoid therapeutics. Understanding of the human system of lipids and receptors has sparked new scientific research into cannabinoids that may affect a much broader range of physiological functions than previously considered. With a tsunami of innovation, cannabinoid biopharmaceutical companies now research, identify and develop new drug candidates to improve and extend patients’ lives, create unique therapeutics to treat multiple maladies and provide new solutions for unmet medical needs.

At the vanguard of biopharmaceutical advancements in cannabinoid therapeutics, Teewinot Life Sciences Corporation has emerged as a leader in the manufacture and delivery of products containing cannabinoids, cannabinoid analogs (modified to enhance efficacy), and cannabinoid prodrugs (activated by body metabolism). Teewinot’s patent-protected biosynthetic cannabinoid manufacturing processes, called CANNSYNTHESIS®, are substantially more efficient than conventional chemical synthesis or methods of botanical extraction from the cannabis plant. The company’s patent protected processes for production of pure cannabinoids utilize biocatalysts and synthetic biology. With its wholly owned subsidiaries, Teewinot Technologies Ltd. (fka Full Spectrum Laboratories Ltd.) and Teewinot Laboratories Inc. (fka CMH Biotechnologies), both domiciled in legally favorable jurisdictions, Teewinot has created novel methods of cannabinoid production that reduce cost and production time while increasing purity.

Teewinot’s unique ability to cost effectively manufacture industrial quantities of exact cannabinoid molecules and modify delivery methods may become an indispensable asset in the global quest to develop effective new cannabinoid therapeutics. The company’s system diversifies the number and types of molecules that can be made available for research, product development and commercial pharmaceutical production of potentially life-changing drugs.

To protect this invaluable asset, Teewinot has taken aggressive intellectual property protection actions and filed patent applications in key countries around the world. Teewinot has created an exceptional combination of cutting edge scientific research on cannabinoids and an aggressive intellectual property portfolio to develop new and improved patient therapies and build significant value.

A myriad of cannabinoid-based drugs may soon be developed to unlock a vast range of new therapeutics that benefit millions of ailing people and answer lingering unmet medical needs. These new-found therapeutics have the potential to create a bonanza in the biopharmaceutical sector, and Teewinot may well become the beneficiary.

For more information, visit the company’s website at www.TLSCorp.com

Let us hear your thoughts: Teewinot Life Sciences Message Board

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php